Table II.
Association between patient characteristics and overall survival time.
| Variables | n | MST, months (95% CI) | P-value (Univariate analysis) | HR (95% CI) | P-value (Multivariate analysis) |
|---|---|---|---|---|---|
| Gender | |||||
| Female | 111 | 16 (13.1–18.9) | 0.380 | 0.952 (0.694–1.307) | 0.761 |
| Male | 281 | 17 (13.1–18.9) | |||
| Age, years | |||||
| <60 | 212 | 18 (16.2–19.8) | 0.066 | 0.994 (0.791–1.249) | 0.958 |
| ≥60 | 180 | 15 (12.7–17.3) | |||
| Smoking status | |||||
| Non-smoker | 194 | 18 (15.6–20.4) | 0.241 | 0.829 (0.616–1.115) | 0.214 |
| Current smoker | 198 | 6 (13.9–18.1) | |||
| Histology type | |||||
| Sq | 132 | 18 (15.7–20.3) | 0.102 | 0.898 (0.682–1.164) | 0.416 |
| Non-Sq | 260 | 16 (14.0–18.0) | |||
| Stage | |||||
| I–II | 40 | 36 (29.5–50.5) | <0.001 | 2.099 (1.756–2.510) | <0.001 |
| III | 209 | 17 (14.8–19.2) | |||
| IV | 143 | 13 (11.8–14.2) | |||
| Regimen | |||||
| GP | 54 | 18 (16.8.0–23.2) | 0.060 | 0.952 (0.866–1.046) | 0.304 |
| TP | 204 | 15 (12.6–17.4) | |||
| DP | 85 | 17 (15.4–18.6) | |||
| CAP | 25 | 14 (9.4–18.6) | |||
| NP | 24 | 18 (12.8–23.2) | 0.539 (0.451–0.643) | <0.001 | |
| Cycles | |||||
| 2–3 | 184 | 12 (10.6–13.4) | <0.001 | ||
| 4–5 | 148 | 19 (17.7–24.3) | |||
| ≥6 | 60 | 23 (19.8–32.2) | |||
| Platinum | |||||
| DDP | 202 | 15 (13.4–16.6) | 0.023 | 0.764 (0.607–0.962) | 0.022 |
| NDP | 190 | 20 (17.0–2.30) |
Sq, squamous cancer; GP, gemcitabine + platinum; TP, paclitaxel + platinum; DP, docetaxe + platinum; CAP, cyclophosphamide + doxorubicin + platinum; NP, navelbine + platinum; DDP, cisplatin; NDP, nedaplatin; MST, median survival time; HR, hazard ratio.